Form 4: Director An van Es-Johansson Acquires Stock Options in Plus Therapeutics, Inc.

An van Es-Johansson, a director of Plus Therapeutics, Inc., acquired stock options exercisable for 3,650 shares of common stock on September 11, 2024.

Summary

• On September 11, 2024, An van Es-Johansson, a director of Plus Therapeutics, Inc. (PSTV), acquired stock options.
• The options grant the right to buy 3,650 shares of Plus Therapeutics' common stock at an exercise price of $1.26 per share.
• The options vest monthly over 12 months from the grant date, or in full at the next annual meeting of stockholders, contingent upon continued service.
• Following the transaction, van Es-Johansson directly owns 3,650 derivative securities (stock options).

Sentiment

Score: 6

Explanation: Neutral sentiment. The filing simply reports a transaction. The acquisition of options by a director could be interpreted as a positive signal, but without further context, it's difficult to gauge the overall impact.

Positives

• The acquisition of stock options by a director could be seen as a positive sign, indicating confidence in the company's future performance.

Industry Context

Form 4 filings are standard disclosures required by the SEC when insiders (officers, directors, and 10% owners) of a publicly traded company buy or sell the company's securities. This filing provides transparency into the transactions of company insiders.

Stakeholder Impact

• The acquisition of stock options by a director may have a minor positive impact on shareholder sentiment.

Key Dates

Keywords

Form 4, Beneficial Ownership, Stock Options, Director, Plus Therapeutics, PSTV, van Es-Johansson